Alpharadin (radium-223)

///Alpharadin (radium-223)

Quality Control Of Xofigo – Confirming That Intravenous Radium-223 Actually Becomes Systemic and Doesn’t Leak At The Injection Site

Radium-223 dichloride (Xofigo) has been approved as an intravenous radiotherapy for men with castration-resistant prostate cancer (CRPC) who have multiple osseous (bone) metastases. Most often, it is used in men who have too many metastases to treat with spot radiation.

Xofigo works by mimicking calcium that is attracted to bones. To be successful the drug must successfully circulate through out the body to be able to find all of the metastases. A recent study evaluated the ability of the intravenous introduction of the Xofigo to properly circulate through the body.

The researchers relied on the fact that […]

NICE Reverses Its Decision and Now Recommends Radium-223 (Xofigo) For Men Who Have Had Chemotherapy

According to Prostate Cancer UK The National Institute for Health and Care Excellence (NICE) has released its second draft decision on the availability of radium-223 (Xofigo). Different from the original draft this draft recommends that radium-223 be made available on the NHS for men with advanced prostate cancer that no longer responds to hormone therapy (castrate resistant prostate cancer) that has also spread to the bones. However, they only recommend it for these men if they’ve already been treated with chemotherapy.

The Scottish Medicines Consortium (SMC), which operates independently of NICE, hasn’t yet considered radium-223 availability on the NHS in Scotland. […]

A New Plant to Manufactor Radium-223 Dichloride (Xofigo) Is Scheduled To Be Built

A few weeks during a devistating manufactoring problem and eventual shut down of all production many men who were relying on Xofigo (radium-233 dichloride) were put into the untenable position of missing their scheduled doses. There was mass confusion about what to do in this circumstance. Men and their doctors didn’t know if they should just continue to wait for the problem’s resolution or to move on to a different drug. When the problem was resolved there was no evidence based information that could guide men if they should just start taking their Xofigo where they left […]

Xofigo Pricing To Change With Patient Costs To Be Reliant On Weight Sensitive Dosages

As of January 1, 2015 there will be some significant changes in the billing and reimbursement schedule for men receiving Bayer healthcare’s radium Ra223 dichloride (Xofigo). Xofigo is FDA approved for the treatment of men with castration-resistant metastatic prostate cancer (mCRPC) who have symptomatic bone metastases and no known visceral metastatic disease. These changes result from the following determinations from the Centers for Medicare & Medicaid Services (CMS).

• CMS has assigned a new permanent Healthcare Common Procedure Coding System (HCPCS) code to Xofigo. This code, A9606 (Radium ra-233 […]